Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2003 by Heidelberg University.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Heidelberg University
Information provided by:
Heidelberg University
ClinicalTrials.gov Identifier:
NCT00221832
First received: September 14, 2005
Last updated: January 12, 2010
Last verified: October 2003
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is the identification of familial congenital arrhythmogenic disorders and their clinical follow-up.
| Condition |
|---|
|
Long QT Syndrome Hypertrophic Cardiomyopathy Arrhythmogenic Right Ventricular Dysplasia |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Prospective |
| Official Title: | Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases |
Resource links provided by NLM:
Genetics Home Reference related topics:
Andersen-Tawil syndrome
Brugada syndrome
Jervell and Lange-Nielsen syndrome
Romano-Ward syndrome
arrhythmogenic right ventricular cardiomyopathy
familial hypertrophic cardiomyopathy
short QT syndrome
supravalvular aortic stenosis
MedlinePlus related topics:
Cardiomyopathy
Genetic and Rare Diseases Information Center resources:
Brugada Syndrome
Arrhythmogenic Right Ventricular Dysplasia
Aortic Valve Stenosis
U.S. FDA Resources
Further study details as provided by Heidelberg University:
Biospecimen Retention: Samples With DNA
Detailed Description:
no biospecimens are to be retained.
| Estimated Enrollment: | 300 |
| Study Start Date: | October 2003 |
| Estimated Study Completion Date: | December 2011 |
Molecular genetic screening in patients with:
- supraventricular
- ventricular arrhythmia
- syncopes of unknown origin and/or suspicion of an arrhythmogenic origin
- family members of patients with sudden cardiac death and aborted sudden cardiac death
Examination of patients includes routine testing like electrocardiogram (ECG), sequential ECGs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance imaging, intravenous drug challenge for identification/exclusion of eg Brugada syndrome. Examples are patients with Long QT Syndrome, Short QT Syndrome, Brugada Syndrome, familial atrial fibrillation, WPW-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Blood samples are taken for further molecular genetic screening.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Consecutive patient sampling with history of syncope, aborted SCD, familial sudden cardiac death, high suspicion of familial cardiac arrhythmias.
Criteria
Inclusion Criteria:
- Patients with a history of syncope, abnormal ECG and suspicion of an arrhythmogenic disease
- Patients with long QT syndrome
- Patients with short QT syndrome, shortened QT intervals, borderline shortened QT intervals
- Patients with Brugada syndrome
- Patients with hypertrophic cardiomyopathy
- Patients with arrhythmogenic right ventricular dysplasia
Exclusion Criteria:
- Inability to understand study protocol
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00221832
Please refer to this study by its ClinicalTrials.gov identifier: NCT00221832
Contacts
| Contact: Christian Wolpert, MD | +49-621-383-2206 | christian.wolpert@med.ma.uni-heidelberg.de | |
| Contact: Rainer Schimpf, MD | +49-621-383-2206 | rainer.schimpf@med.ma.uni-heidelberg.de |
Locations
| Germany | |
| University Hospital Mannheim, I. Department of Medicine | Recruiting |
| Mannheim, Germany, 68167 | |
| Contact: Christian Wolpert, MD +49-621-3832206 christian.wolpert@med.ma.uni-heidelberg.de | |
| Contact: Rainer Schimpf, MD +49-621-3832206 rainer.schimpf@med.ma.uni-heidelberg.de | |
| Principal Investigator: Christian Wolpert, MD | |
Sponsors and Collaborators
Heidelberg University
Investigators
| Study Director: | Martin Borggrefe, Prof., MD | I. Department of Medicine-Cardiology |
More Information
| Responsible Party: | Prof. C. Wolpert, I. Department of Medicine-Cardiology, University Hospital Mannheim, . Department of Medicine-Cardiology, University Hospital Mannheim |
| ClinicalTrials.gov Identifier: | NCT00221832 History of Changes |
| Other Study ID Numbers: | 0261.5 |
| Study First Received: | September 14, 2005 |
| Last Updated: | January 12, 2010 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by Heidelberg University:
|
Long QT Syndrome Hypertrophic cardiomyopathy arrhythmogenic right ventricular dysplasia Short QT Syndrome Brugada Syndrome |
Additional relevant MeSH terms:
|
Long QT Syndrome Syndrome Cardiomyopathies Hypertrophy Cardiomyopathy, Hypertrophic Arrhythmogenic Right Ventricular Dysplasia Disease Pathologic Processes Heart Diseases |
Cardiovascular Diseases Pathological Conditions, Anatomical Aortic Stenosis, Subvalvular Aortic Valve Stenosis Heart Valve Diseases Arrhythmias, Cardiac Heart Defects, Congenital Cardiovascular Abnormalities Congenital Abnormalities |
ClinicalTrials.gov processed this record on September 23, 2016